Aptar Digital Health today announced a collaboration with Guy’s and St Thomas’ NHS Foundation Trust, a leading Trust in London, United Kingdom, to evaluate the impact of Aptar Digital Health’s Respiratory Disease Management Platform, ADH Respiratory DMP, on asthma patients. Both organizations are partnering with the Clinical Research Organization (CRO) Lindus Health to execute this asthma clinical study.
The clinical study, which began in July 2024 and will run for six months, will recruit 118 adults with moderate to severe asthma, with the primary aim of assessing the improvement of asthma symptom control.
During the study, clinical data, including asthma control symptoms, quality of life, asthma controller medication adherence, healthcare resource utilization and overall satisfaction with the digital solution, will be evaluated.
About Aptar Digital Health’s ADH Respiratory DMP
The ADH Respiratory DMP is designed to improve asthma symptom control, technique and engagement. It includes a patient mobile application that connects to inhaler sensors, such as Aptar Digital Health’s HeroTracker® Sense, and a software portal for healthcare professionals. It aims to empower individuals by offering medication and symptoms ith real-time tracking, reminders and educational resources via a mobile app. By fostering behavior change and facilitating adherence, this digital platform aims to reduce asthma symptoms, rescue medication usage, exacerbations and unnecessary healthcare visits.
Geneviève d’Orsay, Chief Medical Officer at Aptar Digital Health, said, “Asthma affects 334 million people worldwide, with between a third and one-half of asthma sufferers having severe symptoms that regularly interfere with everyday life. Our respiratory platform previously demonstrated potential to improve asthma control and decrease rescue medication use in the U.S., and we are excited to study our enhanced platform as part of this real-world study.”
Added Pierre Leurent, President Patient Services and Digital Health at Aptar Pharma, “Enhancing the patient experience is the mission of Aptar Digital Health and we are delighted to achieve this through our collaboration with Guy’s and St Thomas’ NHS Foundation Trust, a leading healthcare organization. Effective management of asthma is necessary to mitigate the consequences of the disease, and we believe that digital solutions can deliver a positive impact on the lives of people affected.”
Professor David Jackson, Consultant in Asthma & Eosinophilic Lung Diseases at Guy’s and St Thomas’ NHS Foundation Trust, and Chief Investigator of the clinical study, commented, “Poor adherence to inhaled steroids remains the biggest barrier to asthma control. At the same time, a failure to identify and correct suboptimal adherence leads to unnecessary escalation to very costly biologic agents due to the incorrect assumption many patients have severe asthma when they do not. As such, electronic monitoring of ICS adherence has enormous potential to both improve quality of care and reduce healthcare costs in asthma, and we are excited to start this study with the aim of demonstrating this.”
Read full Press Release.
